BARGELLINI, Irene
BARGELLINI, Irene
SCIENZE CHIRURGICHE
About the Recently Published Paper on JAMA Oncology “Radioembolization Plus Chemotherapy for First-Line Treatment of Locally Advanced Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial”
2020-01-01 Bargellini I.; Vivaldi C.; Crocetti L.; Masi G.
Addition of Y-90 radioembolization increases tumor response and local disease control in hepatocellular carcinoma patients receiving sorafenib
2022-01-01 Ocal O.; Schutte K.; Zech C.J.; Loewe C.; van Delden O.; Vandecaveye V.; Verslype C.; Gebauer B.; Sengel C.; Bargellini I.; Iezzi R.; Philipp A.; Berg T.; Klumpen H.J.; Benckert J.; Pech M.; Gasbarrini A.; Amthauer H.; Bartenstein P.; Sangro B.; Malfertheiner P.; Ricke J.; Seidensticker M.
An unusual cause of failure in Zenith Alpha Abdominal endograft
2022-01-01 Berchiolli R.N.; Marconi M.; Bargellini I.; Bertagna G.; Adami D.; Mocellin D.M.; Cioni R.; Ferrari M.; Nicola T.
Assessment of radiation sensitivity of unresectable intrahepatic cholangiocarcinoma in a series of patients submitted to radioembolization with yttrium-90 resin microspheres
2021-01-01 Depalo T.; Traino A.C.; Bargellini I.; Lorenzoni G.; Bozzi E.; Vivaldi C.; Lamastra R.; Masi G.; Cioni R.; Boni G.; Volterrani D.
CIRSE Guidelines on Percutaneous Needle Biopsy (PNB)
2017-01-01 Veltri, Andrea; Bargellini, Irene; Giorgi, Luigi; Almeida, Paulo Alexandre Matos Silva; Akhan, Okan
Comparison between Y90 radioembolization plus sorafenib and Y90 radioembolization alone in the treatment of hepatocellular carcinoma: A propensity score analysis
2020-01-01 Facciorusso A.; Bargellini I.; Cela M.; Cincione I.; Sacco R.
Correlation of liver enhancement in gadoxetic acid–enhanced MRI with liver functions: a multicenter-multivendor analysis of hepatocellular carcinoma patients from SORAMIC trial
2022-01-01 Ocal O.; Peynircioglu B.; Loewe C.; van Delden O.; Vandecaveye V.; Gebauer B.; Zech C.J.; Sengel C.; Bargellini I.; Iezzi R.; Benito A.; Schutte K.; Gasbarrini A.; Seidensticker R.; Wildgruber M.; Pech M.; Malfertheiner P.; Ricke J.; Seidensticker M.
Defining textbook outcome for selective internal radiation therapy of hepatocellular carcinoma: an international expert study
2023-01-01 Gregory J.; Tselikas L.; Allimant C.; de Baere T.; Bargellini I.; Bell J.; Bilbao J.I.; Bouvier A.; Chapiro J.; Chiesa C.; Decaens T.; Denys A.; Duran R.; Edeline J.; Garin E.; Ghelfi J.; Helmberger T.; Irani F.; Lam M.; Lewandowski R.; Liu D.; Loffroy R.; Madoff D.C.; Mastier C.; Salem R.; Sangro B.; Sze D.; Vilgrain V.; Vouche M.; Guiu B.; Ronot M.
Drug-eluting Microspheres Compared to Conventional Transarterial Chemoembolization as First Line Treatment for Unresectable Hepatocellular Carcinoma: A Single-center Retrospective Cost-utility Analysis
2023-01-01 Andreozzi G.; Lorenzoni V.; Bargellini I.; Cioni R.; Turchetti G.
Duration of response after DEB-TACE compared to lipiodol-TACE in HCC-naïve patients: a propensity score matching analysis
2021-01-01 Bargellini I.; Lorenzoni V.; Lorenzoni G.; Scalise P.; Andreozzi G.; Bozzi E.; Giorgi L.; Cervelli R.; Scandiffio R.; Perrone O.; Meccia D.V.; Boccuzzi A.; Daviddi F.; Cicorelli A.; Lunardi A.; Crocetti L.; Turchetti G.; Cioni R.
Early tumor shrinkage and response assessment according to mRECIST predict overall survival in hepatocellular carcinoma patients under sorafenib
2022-01-01 Ocal O.; Schinner R.; Schutte K.; de Toni E.N.; Loewe C.; van Delden O.; Vandecaveye V.; Gebauer B.; Zech C.J.; Sengel C.; Bargellini I.; Gasbarrini A.; Sangro B.; Pech M.; Malfertheiner P.; Ricke J.; Seidensticker M.; Kettner E.; Amthauer H.; Cwikla J.; Walecki J.; Klumpen H.; Schott E.; Kolligs F.; Rosmorduc O.; Menu Y.; Leroy V.; Mayerle J.; Trumm C.; Bartenstein P.; Reiser M.; Berg T.; Moche M.; Bilbao I.; Gossner L.; Reimer P.; Popovic P.; Stabuc B.; Piasecki P.; Podgajny Z.; Sacco R.; Peck-Radosavljevic M.; Lammer J.; Maleux G.; Verslype C.; Rosenberg C.; Nitsche D.; Waldenberger P.; Vergniol J.; Cassinotto C.; Yalcin S.; Peynircioglu B.; Zavaglia C.; Rampoldi A.; Tran A.; Chevallier P.; Anty R.; Trautwein C.; Kuhl C.; Grazioli L.; Vogl T.; Trojan J.; Bartolozzi C.; Iezzi R.; Bronowicki J.P.; Palmer D.; Evans J.; Sharma R.; Weir G.; Hubner R.; Basu B.; Ross P.
Early-Stage HCC Percutaneous Locoregional Management: East versus West Perspectives
2023-01-01 Iezzi R.; Posa A.; Contegiacomo A.; Lee I.J.; Bale R.; Tanzilli A.; Tenore L.; Giuliante F.; Gasbarrini A.; Goldberg S.N.; Jakobs T.; Pompili M.; Bargellini I.; Sala E.; Kim H.-C.
Effect of direct endovascular revascularization based on the angiosome model on risk of major amputations and life expectancy in type 2 diabetic patients with critical limb ischemia and foot ulceration
2021-01-01 Iacopi E.; Coppelli A.; Goretti C.; Bargellini I.; Cicorelli A.; Cioni R.; Piaggesi A.
Efficacy of combined transarterial radioembolization and sorafenib in the treatment of hepatocarcinoma: A meta-analysis
2022-01-01 Facciorusso A.; Paolillo R.; Tartaglia N.; Ramai D.; Mohan B.P.; Cotsoglou C.; Chandan S.; Ambrosi A.; Bargellini I.; Renzulli M.; Sacco R.
Extrahepatic Disease in Hepatocellular Carcinoma: Do We Always Need Whole-Body CT or Is Liver MRI Sufficient? A Subanalysis of the SORAMIC Trial
2022-01-01 Geyer T.; Kazmierczak P.M.; Steffen I.G.; Malfertheiner P.; Peynircioglu B.; Loewe C.; van Delden O.; Vandecaveye V.; Gebauer B.; Pech M.; Sengel C.; Bargellini I.; Iezzi R.; Benito A.; Zech C.J.; Gasbarrini A.; Schutte K.; Ricke J.; Seidensticker M.
Gadoxetic acid uptake as a molecular imaging biomarker for sorafenib resistance in patients with hepatocellular carcinoma: a post hoc analysis of the SORAMIC trial
2022-01-01 Öcal O.; Rössler D.; Gasbarrini A.; Berg T.; Klümpen H.J.; Bargellini I.; Peynircioglu B.; van Delden O.; Schulz C.; Schütte K.; Iezzi R.; Pech M.; Malfertheiner P.; Sangro B.; Ricke J.; Seidensticker M.
Gadoxetic acid-based hepatobiliary MRI in hepatocellular carcinoma
2020-01-01 Ricke J.; Steffen I.G.; Bargellini I.; Berg T.; Bilbao Jaureguizar J.I.; Gebauer B.; Iezzi R.; Loewe C.; Karcaaltincaba M.; Pech M.; Sengel C.; van Delden O.; Vandecaveye V.; Zech C.J.; Seidensticker M.
Gadoxetic Acid-Based MRI for Decision-Making in Hepatocellular Carcinoma Employing Perfusion Criteria Only—A Post Hoc Analysis from the SORAMIC Trial Diagnostic Cohort
2022-01-01 Seidensticker M.; Steffen I.G.; Bargellini I.; Berg T.; Benito A.; Gebauer B.; Iezzi R.; Loewe C.; Karcaaltincaba M.; Pech M.; Sengel C.; van Delden O.; Vandecaveye V.; Zech C.J.; Ricke J.
Gastrointestinal bleeding in patients with sars-cov-2 infection managed by interventional radiology
2021-01-01 Ierardi A.M.; Coppola A.; Tortora S.; Valconi E.; Piacentino F.; Fontana F.; Stellato E.; Cogliati C.B.; Torzillo D.; Giampalma E.; Renzulli M.; Bargellini I.; Cioni R.; Scandiffio R.; Spinazzola A.; Foa R.A.; Del Giudice C.; Venturini M.; Carrafiello G.
Impact of body composition in advanced hepatocellular carcinoma: A subanalysis of the SORAMIC trial
2023-01-01 Surov A.; Thormann M.; Hinnerichs M.; Seidensticker M.; Seidensticker R.; Ocal O.; Schutte K.; Zech C.J.; Loewe C.; van Delden O.; Vandecaveye V.; Verslype C.; Gebauer B.; Sengel C.; Bargellini I.; Iezzi R.; Berg T.; Klumpen H.J.; Benckert J.; Gasbarrini A.; Amthauer H.; Sangro B.; Malfertheiner P.; Omari J.; Wienke A.; Ricke J.; Pech M.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| About the Recently Published Paper on JAMA Oncology “Radioembolization Plus Chemotherapy for First-Line Treatment of Locally Advanced Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial” | 2020 | Bargellini I.; Vivaldi C.; Crocetti L.; Masi G. | |
| Addition of Y-90 radioembolization increases tumor response and local disease control in hepatocellular carcinoma patients receiving sorafenib | 2022 | Ocal O.; Schutte K.; Zech C.J.; Loewe C.; van Delden O.; Vandecaveye V.; Verslype C.; Gebauer B.; Sengel C.; Bargellini I.; Iezzi R.; Philipp A.; Berg T.; Klumpen H.J.; Benckert J.; Pech M.; Gasbarrini A.; Amthauer H.; Bartenstein P.; Sangro B.; Malfertheiner P.; Ricke J.; Seidensticker M. | |
| An unusual cause of failure in Zenith Alpha Abdominal endograft | 2022 | Berchiolli R.N.; Marconi M.; Bargellini I.; Bertagna G.; Adami D.; Mocellin D.M.; Cioni R.; Ferrari M.; Nicola T. | |
| Assessment of radiation sensitivity of unresectable intrahepatic cholangiocarcinoma in a series of patients submitted to radioembolization with yttrium-90 resin microspheres | 2021 | Depalo T.; Traino A.C.; Bargellini I.; Lorenzoni G.; Bozzi E.; Vivaldi C.; Lamastra R.; Masi G.; Cioni R.; Boni G.; Volterrani D. | |
| CIRSE Guidelines on Percutaneous Needle Biopsy (PNB) | 2017 | Veltri, Andrea; Bargellini, Irene; Giorgi, Luigi; Almeida, Paulo Alexandre Matos Silva; Akhan, Okan | |
| Comparison between Y90 radioembolization plus sorafenib and Y90 radioembolization alone in the treatment of hepatocellular carcinoma: A propensity score analysis | 2020 | Facciorusso A.; Bargellini I.; Cela M.; Cincione I.; Sacco R. | |
| Correlation of liver enhancement in gadoxetic acid–enhanced MRI with liver functions: a multicenter-multivendor analysis of hepatocellular carcinoma patients from SORAMIC trial | 2022 | Ocal O.; Peynircioglu B.; Loewe C.; van Delden O.; Vandecaveye V.; Gebauer B.; Zech C.J.; Sengel C.; Bargellini I.; Iezzi R.; Benito A.; Schutte K.; Gasbarrini A.; Seidensticker R.; Wildgruber M.; Pech M.; Malfertheiner P.; Ricke J.; Seidensticker M. | |
| Defining textbook outcome for selective internal radiation therapy of hepatocellular carcinoma: an international expert study | 2023 | Gregory J.; Tselikas L.; Allimant C.; de Baere T.; Bargellini I.; Bell J.; Bilbao J.I.; Bouvier A.; Chapiro J.; Chiesa C.; Decaens T.; Denys A.; Duran R.; Edeline J.; Garin E.; Ghelfi J.; Helmberger T.; Irani F.; Lam M.; Lewandowski R.; Liu D.; Loffroy R.; Madoff D.C.; Mastier C.; Salem R.; Sangro B.; Sze D.; Vilgrain V.; Vouche M.; Guiu B.; Ronot M. | |
| Drug-eluting Microspheres Compared to Conventional Transarterial Chemoembolization as First Line Treatment for Unresectable Hepatocellular Carcinoma: A Single-center Retrospective Cost-utility Analysis | 2023 | Andreozzi G.; Lorenzoni V.; Bargellini I.; Cioni R.; Turchetti G. | |
| Duration of response after DEB-TACE compared to lipiodol-TACE in HCC-naïve patients: a propensity score matching analysis | 2021 | Bargellini I.; Lorenzoni V.; Lorenzoni G.; Scalise P.; Andreozzi G.; Bozzi E.; Giorgi L.; Cervelli R.; Scandiffio R.; Perrone O.; Meccia D.V.; Boccuzzi A.; Daviddi F.; Cicorelli A.; Lunardi A.; Crocetti L.; Turchetti G.; Cioni R. | |
| Early tumor shrinkage and response assessment according to mRECIST predict overall survival in hepatocellular carcinoma patients under sorafenib | 2022 | Ocal O.; Schinner R.; Schutte K.; de Toni E.N.; Loewe C.; van Delden O.; Vandecaveye V.; Gebauer B.; Zech C.J.; Sengel C.; Bargellini I.; Gasbarrini A.; Sangro B.; Pech M.; Malfertheiner P.; Ricke J.; Seidensticker M.; Kettner E.; Amthauer H.; Cwikla J.; Walecki J.; Klumpen H.; Schott E.; Kolligs F.; Rosmorduc O.; Menu Y.; Leroy V.; Mayerle J.; Trumm C.; Bartenstein P.; Reiser M.; Berg T.; Moche M.; Bilbao I.; Gossner L.; Reimer P.; Popovic P.; Stabuc B.; Piasecki P.; Podgajny Z.; Sacco R.; Peck-Radosavljevic M.; Lammer J.; Maleux G.; Verslype C.; Rosenberg C.; Nitsche D.; Waldenberger P.; Vergniol J.; Cassinotto C.; Yalcin S.; Peynircioglu B.; Zavaglia C.; Rampoldi A.; Tran A.; Chevallier P.; Anty R.; Trautwein C.; Kuhl C.; Grazioli L.; Vogl T.; Trojan J.; Bartolozzi C.; Iezzi R.; Bronowicki J.P.; Palmer D.; Evans J.; Sharma R.; Weir G.; Hubner R.; Basu B.; Ross P. | |
| Early-Stage HCC Percutaneous Locoregional Management: East versus West Perspectives | 2023 | Iezzi R.; Posa A.; Contegiacomo A.; Lee I.J.; Bale R.; Tanzilli A.; Tenore L.; Giuliante F.; Gasbarrini A.; Goldberg S.N.; Jakobs T.; Pompili M.; Bargellini I.; Sala E.; Kim H.-C. | |
| Effect of direct endovascular revascularization based on the angiosome model on risk of major amputations and life expectancy in type 2 diabetic patients with critical limb ischemia and foot ulceration | 2021 | Iacopi E.; Coppelli A.; Goretti C.; Bargellini I.; Cicorelli A.; Cioni R.; Piaggesi A. | |
| Efficacy of combined transarterial radioembolization and sorafenib in the treatment of hepatocarcinoma: A meta-analysis | 2022 | Facciorusso A.; Paolillo R.; Tartaglia N.; Ramai D.; Mohan B.P.; Cotsoglou C.; Chandan S.; Ambrosi A.; Bargellini I.; Renzulli M.; Sacco R. | |
| Extrahepatic Disease in Hepatocellular Carcinoma: Do We Always Need Whole-Body CT or Is Liver MRI Sufficient? A Subanalysis of the SORAMIC Trial | 2022 | Geyer T.; Kazmierczak P.M.; Steffen I.G.; Malfertheiner P.; Peynircioglu B.; Loewe C.; van Delden O.; Vandecaveye V.; Gebauer B.; Pech M.; Sengel C.; Bargellini I.; Iezzi R.; Benito A.; Zech C.J.; Gasbarrini A.; Schutte K.; Ricke J.; Seidensticker M. | |
| Gadoxetic acid uptake as a molecular imaging biomarker for sorafenib resistance in patients with hepatocellular carcinoma: a post hoc analysis of the SORAMIC trial | 2022 | Öcal O.; Rössler D.; Gasbarrini A.; Berg T.; Klümpen H.J.; Bargellini I.; Peynircioglu B.; van Delden O.; Schulz C.; Schütte K.; Iezzi R.; Pech M.; Malfertheiner P.; Sangro B.; Ricke J.; Seidensticker M. | |
| Gadoxetic acid-based hepatobiliary MRI in hepatocellular carcinoma | 2020 | Ricke J.; Steffen I.G.; Bargellini I.; Berg T.; Bilbao Jaureguizar J.I.; Gebauer B.; Iezzi R.; Loewe C.; Karcaaltincaba M.; Pech M.; Sengel C.; van Delden O.; Vandecaveye V.; Zech C.J.; Seidensticker M. | |
| Gadoxetic Acid-Based MRI for Decision-Making in Hepatocellular Carcinoma Employing Perfusion Criteria Only—A Post Hoc Analysis from the SORAMIC Trial Diagnostic Cohort | 2022 | Seidensticker M.; Steffen I.G.; Bargellini I.; Berg T.; Benito A.; Gebauer B.; Iezzi R.; Loewe C.; Karcaaltincaba M.; Pech M.; Sengel C.; van Delden O.; Vandecaveye V.; Zech C.J.; Ricke J. | |
| Gastrointestinal bleeding in patients with sars-cov-2 infection managed by interventional radiology | 2021 | Ierardi A.M.; Coppola A.; Tortora S.; Valconi E.; Piacentino F.; Fontana F.; Stellato E.; Cogliati C.B.; Torzillo D.; Giampalma E.; Renzulli M.; Bargellini I.; Cioni R.; Scandiffio R.; Spinazzola A.; Foa R.A.; Del Giudice C.; Venturini M.; Carrafiello G. | |
| Impact of body composition in advanced hepatocellular carcinoma: A subanalysis of the SORAMIC trial | 2023 | Surov A.; Thormann M.; Hinnerichs M.; Seidensticker M.; Seidensticker R.; Ocal O.; Schutte K.; Zech C.J.; Loewe C.; van Delden O.; Vandecaveye V.; Verslype C.; Gebauer B.; Sengel C.; Bargellini I.; Iezzi R.; Berg T.; Klumpen H.J.; Benckert J.; Gasbarrini A.; Amthauer H.; Sangro B.; Malfertheiner P.; Omari J.; Wienke A.; Ricke J.; Pech M. |